decayedlooks
Iron
- Joined
- Sep 22, 2026
- Posts
- 18
- Reputation
- 25
Erda threads are everywhere now and half the info is either fearmongering or downplaying. It's a cancer drug that people are using off-label to grow taller. That sentence alone should tell you what you're getting into. Here's what it actually is, what it does, and what it does to you.
What Erdafitinib Actually Is
Erdafitinib is a pan-FGFR tyrosine kinase inhibitor. It binds to and inhibits FGFR1, FGFR2, FGFR3, and FGFR4. It was approved by the FDA in 2019 under the brand name Balversa for metastatic urothelial carcinoma with FGFR3 genetic alterations.
On .org, the target is FGFR3. FGFR3 is a negative regulator of chondrocyte proliferation and growth plate activity. It's the brake on longitudinal bone growth. People with gain-of-function FGFR3 mutations have achondroplasia, the most common form of dwarfism. Inhibiting FGFR3 removes that brake, which is why erda causes accelerated linear growth in growing children.
The catch: it's not selective. It inhibits all four FGFRs. That's why the side effect profile is worse than more selective FGFR3 inhibitors like TYRA-300. You get the growth benefit but you also get everything else FGFR inhibition does to your body.
What The Human Data Shows
This isn't bro science. There are published case reports of pediatric cancer patients on erdafitinib showing dramatic growth acceleration.
A pre-pubescent child with an FGFR1-mutated tumor experienced rapid skeletal and long bone overgrowth resulting in kyphoscoliosis, reminiscent of patients with congenital FGFR3 loss-of-function mutations. A separate case report in Hormone Research in Paediatrics documented a "dramatic growth spurt" after 6 months of erdafitinib treatment without any evidence of pubertal progression or alterations in sex steroids or IGF-1 levels.
One case from the .org literature: a 15.3 year old started at 7mg, reduced to 5mg after 5 months due to high phosphate, added a binder, and grew 14.3cm in 9 months. That's approximately 1.6cm per month. He also developed severe scoliosis because he grew too fast too quickly.
A 13 year old on 5mg, later reduced to 4mg due to leg pain, diarrhea, and nail changes, grew 9.8cm in 6 months. Also about 1.6cm per month.
So the growth effect is real and it's fast. The problem is that growing 1.5cm per month is not what your body was designed to do. Your spine, tendons, and joints don't keep up.
The Side Effects That Actually Matter
Erda has a long side effect list. Most of it is manageable. A few things are not.
Hyperphosphatemia: This is the most common side effect. FGFR inhibition increases serum phosphate levels. In the THOR-2 trial, hyperphosphatemia occurred in 76% of patients receiving erdafitinib. Most cases were grade 2 but it can be serious. High phosphate leads to mineral deposition in soft tissues, joints, and blood vessels. This is why you need phosphate binders like sevelamer carbonate or lanthanum carbonate. The FDA recommends restricting dietary phosphate to 600-800mg daily and starting a binder if serum phosphate exceeds 7.0 mg/dL.
Central Serous Retinopathy (CSR): This is the scary one. CSR was reported in 17% of patients on erdafitinib in the THOR trial, compared to 0% on chemotherapy. CSR causes fluid accumulation under the retina, which distorts vision. If you see straight lines appear bent or vision goes blurry, you stop immediately. The FDA recommends monthly ophthalmologic monitoring including optical coherence tomography. Most cases resolve after discontinuation but some patients had persistent vision impairment.
Onychomadesis and nail toxicity: Nail disorders including onycholysis, onychomadesis (nail shedding), and nail discoloration occur in 20-30% of patients. It's painful and annoying but not dangerous. It resolves after stopping.
Skeletal toxicity: This is the one that matters most for .org users. A pediatric study found that bony toxicity was uniquely noted in skeletally immature patients, with 4 patients developing limb fractures including 1 with slipped capital femoral epiphysis. Additional bone toxicities included scoliosis and spinal cord compression. Rapid growth velocity is the driver. If you grow faster than your body can structurally accommodate, you get deformities.
Alopecia: Hair loss occurs in about 25% of patients. This is temporary and resolves after stopping.
The mundane shit: Diarrhea, dry mouth, dry skin, dry eyes, stomatitis, fatigue, and appetite loss are all common. Most are manageable with hydration, moisturizer, and loperamide.
Dosing And Cycling
The FDA-approved dose for cancer is 8mg daily with up-titration to 9mg based on phosphate levels. That's not the dose .org users run.
Community consensus is 4-6mg daily for height growth. Some start at 2mg and titrate up. The .org guides recommend cycling 5 weeks on, 2 weeks off to reduce cumulative toxicity and allow phosphate levels to normalize.
The .org "mineralization stack" includes vitamin D, K2, magnesium, and adequate protein. The logic is that rapid bone growth depletes these nutrients and without them you get weak bones and joint pain. Whether this actually prevents skeletal toxicity is unknown.
The Brutal Reality
Erda works. That's not the question. The question is whether the risk is worth it.
The people who get the best results are adolescents with open growth plates who are short and desperate. The people who get the worst outcomes are the same demographic when they grow too fast and develop scoliosis or joint damage that requires surgery.
The FDA doesn't approve this for height. No doctor will prescribe it for height. You're sourcing a cancer drug from research chemical suppliers and dosing yourself based on forum posts. That's the reality of what you're doing.
If you're 16 with open plates and 5'6", erda might get you to 5'9" in a year. It might also give you scoliosis, nail loss, and vision changes. The risk-reward is genuinely unclear because the long-term data doesn't exist. Nobody has studied what happens when healthy adolescents take pan-FGFR inhibitors for 12 months.
Mistakes That Come Up Constantly
TL;DR
Erdafitinib is a pan-FGFR inhibitor that removes the brake on bone growth. It works. The growth rate is real, around 1.5cm per month in reported cases. The side effects are also real: hyperphosphatemia in 76% of patients, CSR in 17%, nail shedding in 20-30%, and skeletal toxicity including scoliosis and fractures in growing kids. If you have open plates and you're desperate, it's an option. If your plates are closed or you're not prepared to monitor phosphate, eyes, and growth velocity religiously, don't touch it.
Sources
What Erdafitinib Actually Is
Erdafitinib is a pan-FGFR tyrosine kinase inhibitor. It binds to and inhibits FGFR1, FGFR2, FGFR3, and FGFR4. It was approved by the FDA in 2019 under the brand name Balversa for metastatic urothelial carcinoma with FGFR3 genetic alterations.
On .org, the target is FGFR3. FGFR3 is a negative regulator of chondrocyte proliferation and growth plate activity. It's the brake on longitudinal bone growth. People with gain-of-function FGFR3 mutations have achondroplasia, the most common form of dwarfism. Inhibiting FGFR3 removes that brake, which is why erda causes accelerated linear growth in growing children.
The catch: it's not selective. It inhibits all four FGFRs. That's why the side effect profile is worse than more selective FGFR3 inhibitors like TYRA-300. You get the growth benefit but you also get everything else FGFR inhibition does to your body.
What The Human Data Shows
This isn't bro science. There are published case reports of pediatric cancer patients on erdafitinib showing dramatic growth acceleration.
A pre-pubescent child with an FGFR1-mutated tumor experienced rapid skeletal and long bone overgrowth resulting in kyphoscoliosis, reminiscent of patients with congenital FGFR3 loss-of-function mutations. A separate case report in Hormone Research in Paediatrics documented a "dramatic growth spurt" after 6 months of erdafitinib treatment without any evidence of pubertal progression or alterations in sex steroids or IGF-1 levels.
One case from the .org literature: a 15.3 year old started at 7mg, reduced to 5mg after 5 months due to high phosphate, added a binder, and grew 14.3cm in 9 months. That's approximately 1.6cm per month. He also developed severe scoliosis because he grew too fast too quickly.
A 13 year old on 5mg, later reduced to 4mg due to leg pain, diarrhea, and nail changes, grew 9.8cm in 6 months. Also about 1.6cm per month.
So the growth effect is real and it's fast. The problem is that growing 1.5cm per month is not what your body was designed to do. Your spine, tendons, and joints don't keep up.
The Side Effects That Actually Matter
Erda has a long side effect list. Most of it is manageable. A few things are not.
Hyperphosphatemia: This is the most common side effect. FGFR inhibition increases serum phosphate levels. In the THOR-2 trial, hyperphosphatemia occurred in 76% of patients receiving erdafitinib. Most cases were grade 2 but it can be serious. High phosphate leads to mineral deposition in soft tissues, joints, and blood vessels. This is why you need phosphate binders like sevelamer carbonate or lanthanum carbonate. The FDA recommends restricting dietary phosphate to 600-800mg daily and starting a binder if serum phosphate exceeds 7.0 mg/dL.
Central Serous Retinopathy (CSR): This is the scary one. CSR was reported in 17% of patients on erdafitinib in the THOR trial, compared to 0% on chemotherapy. CSR causes fluid accumulation under the retina, which distorts vision. If you see straight lines appear bent or vision goes blurry, you stop immediately. The FDA recommends monthly ophthalmologic monitoring including optical coherence tomography. Most cases resolve after discontinuation but some patients had persistent vision impairment.
Onychomadesis and nail toxicity: Nail disorders including onycholysis, onychomadesis (nail shedding), and nail discoloration occur in 20-30% of patients. It's painful and annoying but not dangerous. It resolves after stopping.
Skeletal toxicity: This is the one that matters most for .org users. A pediatric study found that bony toxicity was uniquely noted in skeletally immature patients, with 4 patients developing limb fractures including 1 with slipped capital femoral epiphysis. Additional bone toxicities included scoliosis and spinal cord compression. Rapid growth velocity is the driver. If you grow faster than your body can structurally accommodate, you get deformities.
Alopecia: Hair loss occurs in about 25% of patients. This is temporary and resolves after stopping.
The mundane shit: Diarrhea, dry mouth, dry skin, dry eyes, stomatitis, fatigue, and appetite loss are all common. Most are manageable with hydration, moisturizer, and loperamide.
Dosing And Cycling
The FDA-approved dose for cancer is 8mg daily with up-titration to 9mg based on phosphate levels. That's not the dose .org users run.
Community consensus is 4-6mg daily for height growth. Some start at 2mg and titrate up. The .org guides recommend cycling 5 weeks on, 2 weeks off to reduce cumulative toxicity and allow phosphate levels to normalize.
The .org "mineralization stack" includes vitamin D, K2, magnesium, and adequate protein. The logic is that rapid bone growth depletes these nutrients and without them you get weak bones and joint pain. Whether this actually prevents skeletal toxicity is unknown.
The Brutal Reality
Erda works. That's not the question. The question is whether the risk is worth it.
The people who get the best results are adolescents with open growth plates who are short and desperate. The people who get the worst outcomes are the same demographic when they grow too fast and develop scoliosis or joint damage that requires surgery.
The FDA doesn't approve this for height. No doctor will prescribe it for height. You're sourcing a cancer drug from research chemical suppliers and dosing yourself based on forum posts. That's the reality of what you're doing.
If you're 16 with open plates and 5'6", erda might get you to 5'9" in a year. It might also give you scoliosis, nail loss, and vision changes. The risk-reward is genuinely unclear because the long-term data doesn't exist. Nobody has studied what happens when healthy adolescents take pan-FGFR inhibitors for 12 months.
Mistakes That Come Up Constantly
- Not getting a wrist X-ray first. If your plates are closed, erda does nothing for height and you're just poisoning yourself.
- Skipping phosphate monitoring. Hyperphosphatemia is nearly universal. You need labs every 2-4 weeks and a binder on hand.
- Skipping eye exams. CSR is common and can be permanent if you ignore it. Monthly OCT is the standard.
- Growing too fast. 1.5cm per month sounds amazing until you have scoliosis. Some users cap growth velocity deliberately.
- Running it for months without cycling. The .org standard is 5 weeks on, 2 off. Cumulative toxicity is real.
- Thinking vitamin K2 and magnesium will prevent skeletal toxicity. They might help with mineralization but they won't stop your spine from curving if you grow too fast.
- Buying from random suppliers. Erda powder is expensive and the market is full of underdosed or mislabeled shit.
- Believing transformation posts without X-rays. Most "erda grew me 2 inches in a month" threads are LARP or the person was in a natural growth spurt anyway.
TL;DR
Erdafitinib is a pan-FGFR inhibitor that removes the brake on bone growth. It works. The growth rate is real, around 1.5cm per month in reported cases. The side effects are also real: hyperphosphatemia in 76% of patients, CSR in 17%, nail shedding in 20-30%, and skeletal toxicity including scoliosis and fractures in growing kids. If you have open plates and you're desperate, it's an option. If your plates are closed or you're not prepared to monitor phosphate, eyes, and growth velocity religiously, don't touch it.
Sources
- FDA prescribing information for BALVERSA (erdafitinib)
- Skeletal overgrowth in a pre-pubescent child treated with pan-FGFR inhibitor (Heliyon 2024)
- Accelerated Linear Growth during Erdafitinib Treatment (Hormone Research in Paediatrics 2024)
- THOR-2 final analysis: hyperphosphatemia in 76% of patients
- FDA Clinical Review: Central serous retinopathy in 17% of erdafitinib patients
- Pediatric skeletal toxicity: limb fractures, SCFE, scoliosis, spinal cord compression
- FDA NDA 212018: nail disorder, onycholysis, onychomadesis
- looksmax.org FULL ERDAFITINIB GUIDE GTFIH
- looksmax.org Quick Erda Side Effect Protocol
- looksmax.org Erda experience (45 days, 5mg)
